Background Renal cell carcinoma (RCC) is recognized as a neoplasm resistant to
chemotherapy. In vitro experiments demonstrated that suramin, at noncytotoxic doses …

Twenty-two eligible patients with advanced renal carcinoma were treated with suramin
utilizing a fixed dose regimen. Therapy was reasonably well tolerated with 3 of 22 patients …

Twenty-six patients with advanced renal cell carcinoma were treated with suramin
administered by continuous infusion, with dosing determined by a nomogram. One patient …

This study was conducted to assess the efficacy and toxicity of suramin administered using a
fixed dose schedule in patients with advanced renal cell carcinoma. Fourteen eligible …

Suramin sodium is an aromatic polysulfonated compound that was originally introduced as
an antiparasitic agent in the 1920s. Recently, in view of its ability to bind and disrupt the …

The use of suramin, a polysulfonated naphthylurea, in the treatment of advanced prostate
cancer currently is being investigated. A 52‐year‐old man developed acute renal …

Cisplatin, a commonly used cancer chemotherapeutic, has a dose-limiting side effect of
nephrotoxicity. Approximately 30% of patients administered cisplatin suffer from kidney …

Suramin has demonstrated modest activity against prostate cancer and is being investigated
in clinical trials. We describe a patient with metastatic prostate cancer who developed …

Purpose: Suramin is a polysulfonated naphthylurea that inhibits proliferation and DNA
synthesis of transitional cell carcinoma cell lines. Its large molecular size and negative …

Suramin is polysulfonated napthylurea which has a broad range of antitumor activity. The
mechanism of action of suramin is not completely understood, although it is known to inhibit …